title: Everolimus-associated stomatitis in a patient who had renal transplant.
abstract: Everolimus is used as an immunosuppressant in renal allograft transplant rejection and in metastatic breast cancer treatment. One side effect of everolimus is stomatitis, referred to as mammalian target of rapamycin inhibitor-associated stomatitis. This side effect can affect treatment course and contribute to discontinuation of therapy or dose reduction, previously reported in the treatment of metastatic breast cancer. Here, we present a case of everolimus-associated stomatitis with a novel management method with intralesional triamcinolone that allows for continuous course of everolimus.
authors: Harvard School of Dental Medicine, Boston, Massachusetts, USA.
authors: Yisi D
authors: http://orcid.org/0000-0001-7811-5463
authors: YD
authors: Ji
authors: Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
authors: Ali
authors: A
authors: Aboalela
authors: Department of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, Massachusetts, USA.
authors: Alessandro
authors: A
authors: Villa
mesh_terms: D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D002990:Clobetasol / Q000008:administration & dosage; D003937:Diagnosis, Differential; D000068338:Everolimus / Q000009:adverse effects*; D005260:Female; D005782:Gels; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D008875:Middle Aged; D011183:Postoperative Complications / Q000139:chemically induced / Q000175:diagnosis; D013280:Stomatitis / Q000139:chemically induced* / Q000175:diagnosis
chemical_list: D000893:Anti-Inflammatory Agents; D005782:Gels; D007166:Immunosuppressive Agents; D000068338:Everolimus; D002990:Clobetasol